An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Trial Status: active
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability
following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also
referred to as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617)
in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior
ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).
Inclusion Criteria
Key Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Participants must be adults ≥ 18 years of age.
- Participants must have an ECOG performance status ≤ 1.
- Participants must have histological confirmation of adenocarcinoma of the prostate.
- Participants must be PSMA-positive per 68Ga-PSMA PET/CT scans at baseline
- Participants must have a castrate level of serum/plasma testosterone (< 50 ng/dL or
< 1.7 nmol/L) either by pharmaceutical or surgical methods.
- Participants must have progressed only once on prior second generation ARPIs
- Documented progressive mCRPC
- Participants must have ≥ 1 metastatic lesion by conventional imaging that is present
on screening/baseline CT, MRI, or bone scan
- Renal: eGFR ≥ 60 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation.
- Participants must have recovered to ≤ Grade 2 from all clinically significant
toxicities related to prior therapies except alopecia.
Key exclusion Criteria:
- Previous treatment with any of the following within 6 months of study enrollment:
Strontium 89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body
irradiation
- Any previous radioligand therapy.
- Prior treatment with cytotoxic chemotherapy for metastatic castration-resistant or
metastatic hormone-sensitive prostate cancer (mHSPC) (e.g., taxanes, platinum,
estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy
[including monoclonal antibodies]. [Note: Taxane exposure (maximum 6 cycles) in the
adjuvant or neoadjuvant setting is allowed if 12 months have elapsed since
completion of this adjuvant or neoadjuvant therapy. Prior treatment with
sipuleucel-T is allowed].
- Concurrent therapies: cytotoxic chemotherapy, immunotherapy, radioligand therapy,
PARP inhibitor, biological, or investigational therapy
- History of myocardial infarction (MI), angina pectoris, or coronary artery bypass
graft (CABG) within 6 months prior to ICF signature and/or clinically active
significant cardiac disease
- Concurrent serious acute or chronic nephropathy and/or moderate to severe renal
impairment as determined by the principal investigator.
- Diagnosed with other active malignancies that are expected to alter life expectancy
or may interfere with disease assessment
- Sexually active males unwilling to use a condom during intercourse while taking
study treatment and for 14 weeks after stopping study treatment.
- Concurrent urinary outflow obstruction or unmanageable urinary incontinence
- History of somatic or psychiatric disease/condition that may interfere with the aims
and assessments of the study.
Other protocol-defined inclusion/exclusion criteria may apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06531499.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo Alto
Status: Active
Name Not Available
Minnesota
Rochester
Mayo Clinic in Rochester
Status: Active
Name Not Available
The study includes screening period, treatment period, and a post-treatment follow-up
period.
Screening Period: Approximately 106 participants will be enrolled to receive up to12
consecutive cycles of AAA617. Potential participants will be assessed for eligibility by
verifying their baseline PSMA PET scan for mandatory confirmation of PSMA positivity
prior to first cycle by local review.
Treatment Period: Eligible participants will be treated with up to 12 cycles of 7.4 GBq
AAA617 intravenously every 6 weeks, until radiographic progression, toxicity leading to
treatment discontinuation, death, loss to follow-up, or withdrawal of consent, whichever
occurs first. During treatment period, all participants who complete the initial 6 cycles
of AAA617 treatment will undergo an additional PSMA-PET scan after Cycle 6 to re-assess
PSMA expression level and to reassess eligibility of participants to receive additional
AAA617 treatment cycles.
Post-Treatment Follow-Up: All participants will undergo a PSMA-PET scan at end of
treatment (EOT). The post-treatment follow-up period will consist of EOT; 42-days safety;
EOT RLI; safety, survival and rPFS follow-up visits.
The planned duration of treatment period is up to 74 weeks with treatment given every 6
weeks. Participants may be discontinued from treatment earlier due to unacceptable
toxicity or disease progression, and/or at the discretion of the Investigator or the
participant.
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationNovartis Pharmaceuticals Corporation
